Advanomics Corporation, the Parent Company of Sunshine Biopharma, Files a New Patent Application for Its Multidrug Resistance Adva-27a Anticancer Compound

MONTREAL -- (Marketwire) -- 01/15/13 -- Advanomics Corporation, the parent company of Sunshine Biopharma Inc. (OTCQB:…

Continue Reading

Sunshine Biopharma Completes Six IND-Enabling Studies for Its Anticancer Compound, Adva-27a

MONTREAL -- (Marketwire) -- 12/04/12 -- Sunshine Biopharma Inc. (OTCBB: SBFM), a pharmaceutical company focused on…

Continue Reading

Advanomics Corporation, the Parent Company of Sunshine Biopharma, Completes Acquisition of Adva-27a Patents

MONTREAL -- (Marketwire) -- 11/27/12 -- Advanomics Corporation, the parent company of Sunshine Biopharma Inc. (OTCQB:…

Continue Reading

Sunshine Biopharma Initiates IND-Enabling Studies for Its Anticancer Compound, Adva-27a

MONTREAL -- (Marketwire) -- 11/13/12 -- Sunshine Biopharma Inc. (OTCBB: SBFM), a pharmaceutical company focused on…

Continue Reading

Sunshine Biopharma Receives Scale-Up Manufacturing Protocol for Its Lead Anti-Cancer Compound, Adva-27a

MONTREAL -- (Marketwire) -- 10/09/12 -- Sunshine Biopharma Inc. (OTCBB: SBFM), a pharmaceutical company focused on…

Continue Reading

Sunshine Biopharma Announces Submission of an Adva-27a Manuscript for Publication in a Peer-Reviewed Scientific Journal

MONTREAL -- (Marketwire) -- 08/15/12 -- Sunshine Biopharma Inc. (OTCBB: SBFM), a pharmaceutical company focused on…

Continue Reading